Skip to content

BIO-FUNCTION for Prediction Non Relapse Mortality in Transplant and Cell Therapy

BIO-FUNCTION for NRM Prediction in SCTCT: Assessing Biological and Functional Reserve to Predict Non-Relapse Mortality in Stem Cell Transplant and Cell Therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07769151
Enrollment
124
Registered
2026-08-17
Start date
2026-09-01
Completion date
2031-12-30
Last updated
2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mortality Prediction

Brief summary

The purpose of this research is test if combination of physical tests and blood tests drawn before SCTCT can predict NRM.

Interventions

DIAGNOSTIC_TESTblood sample to check CXCL9 pre stem cell transplant and cell therapy

Pre SCTCT as per SOC physical function assessment will be performed in a form of IADl, hand grip, and or walk test like TUG. Specimen Collection Studies: LDH , albumin, ferritin, CRP, platelet and creatinine will be collected as per standard of care pre SCTCT. The non-SOC procedure will be drawing CXL9

Sponsors

Henry Ford Health System
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients \>18 year old planned for SCTCT

Exclusion criteria

* Pregnancy, prisoners , Patients with a serious medical or psychiatric illness likely to interfere with participation in this clinical study

Design outcomes

Primary

MeasureTime frame
Non relapse mortality (NRM)NRM at day 100 and at year 1

Countries

United States

Contacts

CONTACTShatha Farhan, MD
sfarhan1@hfhs.org3137133910

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026